首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Expression of cytokeratin 8 in lung cancer cell lines and measurement of serum cytokeratin 8 in lung cancer patients.
【24h】

Expression of cytokeratin 8 in lung cancer cell lines and measurement of serum cytokeratin 8 in lung cancer patients.

机译:肺癌细胞系中细胞角蛋白8的表达及肺癌患者血清细胞角蛋白8的测定。

获取原文
获取原文并翻译 | 示例
           

摘要

It has been reported that cytokeratin 8 (CK8) can be expressed in several cancers and expression of CK8 is correlated with increased invasiveness of the tumor in vitro and in vivo. In the present study, we investigated expressions of CK8 in human lung cancer cell lines. In addition, we also evaluated the clinical significance of CK8 measurements in sera of patients with lung cancer. Expression of mRNA for CK8 was semi-quantitatively evaluated by the competitive reverse transcriptase-polymerase chain reaction (competitive RT-PCR), using human lung cancer cell lines. The level of CK8 protein in culture supernatants of lung cancer cell lines and 70 sera of patients with lung cancer was measured by enzyme-linked immunosorbent assay (ELISA). Levels of serum CK8 according to clinical parameters were also examined. The level of expression of CK8 mRNA in non-small cell lung cancer (NSCLC) cell lines was significantly high compared with that of small cell lung cancer (SCLC) cell lines (P<0.05). The level of CK8in culture supernatants in NSCLC was significantly high compared with that of SCLC. The level of serum CK8 in patients with NSCLC was significantly high compared with that of normal non-smokers and compared with that of SCLC (P<0.05). Patients with a CK8 value of 50.0 ng/ml, or higher, had a statistically significant diminished survival compared with those patients whose CK8 values were lower. In conclusion, CK8 was preferentially expressed in NSCLC. Increasing values of CK8 were significantly associated with tumor progression and decreased survival in patients with NSCLC. Therefore, CK8 in sera may become a novel tumor marker in patients with lung cancer.
机译:据报道,细胞角蛋白8(CK8)可以在几种癌症中表达,并且CK8的表达与体外和体内肿瘤的侵袭性增加相关。在本研究中,我们调查了CK8在人肺癌细胞系中的表达。此外,我们还评估了肺癌患者血清中CK8检测的临床意义。使用人肺癌细胞系,通过竞争逆转录聚合酶链反应(竞争性RT-PCR)半定量评估CK8的mRNA表达。通过酶联免疫吸附试验(ELISA)检测肺癌细胞株和70血清肺癌患者培养上清液中CK8的水平。还根据临床参数检查了血清CK8的水平。与小细胞肺癌(SCLC)细胞相比,非小细胞肺癌(NSCLC)细胞中CK8 mRNA的表达水平显着较高(P <0.05)。与SCLC相比,NSCLC中培养上清液中CK8的水平显着较高。与正常非吸烟者和SCLC相比,NSCLC患者的血清CK8水平显着较高(P <0.05)。与CK8值较低的患者相比,CK8值为50.0 ng / ml或更高的患者的存活率在统计学上显着降低。总之,CK8在NSCLC中优先表达。 CK8值的升高与NSCLC患者的肿瘤进展和生存期降低显着相关。因此,血清CK8可能成为肺癌患者的新型肿瘤标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号